GREENWICH LIFESCIENCES, INC. Basic Shares Outstanding (Weighted Average)
GREENWICH LIFESCIENCES, INC. (GLSI) reported Basic Shares Outstanding (Weighted Average) of 14.62 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 14.62M shares, a 9.35% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 14.57M shares, a 10.58% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 13.95M shares, a 6.10% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 13.64M shares, a 3.80% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 13.53M shares, a 4.00% increase from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 13.01M shares, a 1.30% increase from fiscal 2023.
- GREENWICH LIFESCIENCES, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 12.85M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 14.62M shares 10-Q · filed 2026-08-11 | 14.68M shares 10-Q · filed 2026-08-11 | 14.38M shares derived: average of 3 quarters · filed 2026-08-11 | 14.19M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 14.57M shares 10-Q · filed 2026-06-04 | 14.26M shares derived: average of 2 quarters · filed 2026-06-04 | 14.05M shares derived: average of 3 quarters · filed 2026-06-04 | 13.88M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 13.95M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | 13.80M shares derived: average of 2 quarters · filed 2026-06-01 | 13.65M shares derived: average of 3 quarters · filed 2026-08-11 | 13.53M shares 10-K · filed 2026-06-01 |
| 2025-09-30 | 13.64M shares 10-Q · filed 2025-11-14 | 13.51M shares derived: average of 2 quarters · filed 2026-08-11 | 13.40M shares 10-Q · filed 2025-11-14 | 13.33M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 13.37M shares 10-Q · filed 2026-08-11 | 13.27M shares 10-Q · filed 2026-08-11 | 13.23M shares derived: average of 3 quarters · filed 2026-08-11 | 13.21M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 13.17M shares 10-Q · filed 2026-06-04 | 13.16M shares derived: average of 2 quarters · filed 2026-06-04 | 13.15M shares derived: average of 3 quarters · filed 2026-06-04 | 13.09M shares derived: average of 4 quarters · filed 2026-06-04 |
| 2024-12-31 | 13.15M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | 13.15M shares derived: average of 2 quarters · filed 2026-06-01 | 13.07M shares derived: average of 3 quarters · filed 2026-06-01 | 13.01M shares 10-K · filed 2026-06-01 |
| 2024-09-30 | 13.14M shares 10-Q · filed 2025-11-14 | 13.02M shares derived: average of 2 quarters · filed 2025-11-14 | 12.97M shares 10-Q · filed 2025-11-14 | 12.94M shares derived: average of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | 12.91M shares 10-Q · filed 2025-08-14 | 12.88M shares 10-Q · filed 2025-08-14 | 12.87M shares derived: average of 3 quarters · filed 2025-08-14 | 12.87M shares derived: average of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | 12.86M shares 10-Q · filed 2025-05-20 | 12.85M shares derived: average of 2 quarters · filed 2025-05-20 | 12.85M shares derived: average of 3 quarters · filed 2025-05-20 | 12.85M shares derived: average of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | 12.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | 12.85M shares derived: average of 2 quarters · filed 2025-04-15 | 12.85M shares derived: average of 3 quarters · filed 2025-04-15 | 12.85M shares 10-K · filed 2025-04-15 |
| 2023-09-30 | 12.85M shares 10-Q · filed 2024-11-14 | 12.85M shares derived: average of 2 quarters · filed 2024-11-14 | 12.85M shares 10-Q · filed 2024-11-14 | |
| 2023-06-30 | 12.85M shares 10-Q · filed 2024-08-14 | 12.85M shares 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 12.85M shares 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |